ClinicalTrials.gg
CompletedNCT03536481Updated Jul 24, 2019

Bioequivalency Study of Ensartinib Capsules in Healthy Volunteers

A Phase 1 interventional study of ensartinib capsules (test product) and ensartinib capsules (reference product) in Lung Cancer, sponsored by Betta Pharmaceuticals Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-24.

Sponsored by Betta Pharmaceuticals Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 845 studies in Lung Neoplasms with a site in China — 372 open to participants now, 419 under way, 34 of them phase 3. Lung Neoplasms · China.

Enrollment
319th of 586
74 · median 90
Started
2018
with 58 others
Phase 1
74 of 845
43 open now
Registered
208th of 845
by date

Among the 845 studies in Lung Neoplasms with a site in China, this one is the 319th largest by enrollment of the 586 interventional ones that give a count, is one of 59 that started in 2018, is one of 74 in phase 1, and was the 208th registered.

Lung Neoplasms

5,427 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

372 of the 845 studies in Lung Neoplasms with a site in China are open now. Recruiting first, the newest first:

367 more — sign in →

All 372 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 995 Lung Neoplasms studies recruiting now, 684 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 845 studies in Lung Neoplasms with a site in China, or all of them as a file.
02

Study summary

The main objective of this study is to evaluate the bioequivalency of two preparations of ensartinib capsules in Chinese healthy volunteers.

Read the detailed description

The main objective of this study is to evaluate the bioequivalency of two preparations of ensartinib capsules in Chinese healthy volunteers under fasted state or after meal. In addition, the safety of single dose administration of ensartinib capsules in Chinese healthy volunteers will also be evaluated.

03

Conditions studied

  • Lung Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male body weight≥50.0kg or female body weight≥45.0kg; between 19.0-26.0 kg/m2(inclusive)
  • Generally in good health, with no history of chronic disease or sever disease
  • No (clinical significant) abnormal findings in clinical laboratory tests and physical examinations
  • No plan for pregnancy in coming 6 months, and must practice effective ; No plan for sperm or egg donation
  • Written

Exclusion criteria

Exclusion Criteria:

  • History of food or drug allergies
  • Clinical significant disease or disorders
  • Received surgery in 3 months before screening, or have plan for surgery during the study
  • Participated in other clinical trials within 3 months before screening
  • Venipuncture intolerance
  • Drug abusing in 6 months
  • Donated ≥200 mL of blood within 30 days before screening
  • Pregnant or under lactation period (female subjects)
  • Received any prescription drug, over-the-counter drug, Chinese herbal drug or vitamins in 2 weeks
  • Received any vaccine in 4 weeks
  • Excessively smoking, alcohol or coffin-containing beverage drinking in 3 months
  • Other circumstances that is deemed not appropriate for the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    T-R cohort under fasted state

    Subjects will be administered with one single dose of ensartinib capsules (test product) under fasted state, after a wash period of 14 days,the subjects will be administered with one single dose of ensartinib capsules (reference product) under fasted state.

    Drug: ensartinib capsules (test product) · Drug: ensartinib capsules (reference product)

  • Experimental
    R-T cohort under fasted state

    Subjects will be administered with one single dose of ensartinib capsules (reference product) under fasted state, after a wash period of 14 days,the subjects will be administered with one single dose of ensartinib capsules (test product) under fasted state.

    Drug: ensartinib capsules (test product) · Drug: ensartinib capsules (reference product)

  • Experimental
    T-R cohort after meal

    Subjects will be administered with one single dose of ensartinib capsules (test product) after meal, after a wash period of 14 days,the subjects will be administered with one single dose of ensartinib capsules (reference product) after meal.

    Drug: ensartinib capsules (test product) · Drug: ensartinib capsules (reference product)

  • Experimental
    R-T cohort after meal

    Subjects will be administered with one single dose of ensartinib capsules (reference product) after meal, after a wash period of 14 days,the subjects will be administered with one single dose of ensartinib capsules (test product) after meal.

    Drug: ensartinib capsules (test product) · Drug: ensartinib capsules (reference product)

Interventions

06

What researchers measure

Primary outcomes

  1. Peak plasma concentration(Cmax) of ensartinib(test product) after meal

    The Cmax of ensartinib(test product) in after meal blood samples of each subject over a 120 hour period post dose

    Time frame: pre-dose(60minute),30min,1,1.5,2,2.5,3,3.5,4,4.5,5,6,8,12,24,36,48,72,96,120hour

  2. Peak plasma concentration(Cmax) of ensartinib(test product) under fasted sate

    The Cmax of ensartinib(test product) in fasting blood samples of each subject over a 120 hour period post dose

    Time frame: pre-dose(60minute),30min,1,1.5,2,2.5,3,3.5,4,4.5,5,6,8,12,24,36,48,72,96,120hour

  3. Peak plasma concentration(Cmax) of ensartinib(reference product) after meal

    The Cmax of ensartinib(reference product) in after meal blood samples of each subject over a 120 hour period post dose

    Time frame: pre-dose(60minute),30min,1,1.5,2,2.5,3,3.5,4,4.5,5,6,8,12,24,36,48,72,96,120hour

  4. Peak plasma concentration(Cmax) of ensartinib(reference product) under fasted sate

    The Cmax of ensartinib(reference product) in fasting blood samples of each subject over a 120 hour period post dose

    Time frame: pre-dose(60minute),30min,1,1.5,2,2.5,3,3.5,4,4.5,5,6,8,12,24,36,48,72,96,120hour

  5. Area under the plasma concentration versus time curve(AUC) of ensartinib(test product) after meal

    The AUC of ensartinib(test product) in after meal blood samples of each subject over a 120 hour period post dose

    Time frame: pre-dose(60minute),30min,1,1.5,2,2.5,3,3.5,4,4.5,5,6,8,12,24,36,48,72,96,120hour

  6. Area under the plasma concentration versus time curve(AUC) of ensartinib(test product) under fasted sate

    The AUC of ensartinib(test product) in fasting blood samples of each subject over a 120 hour period post dose

    Time frame: pre-dose(60minute),30min,1,1.5,2,2.5,3,3.5,4,4.5,5,6,8,12,24,36,48,72,96,120hour

  7. Area under the plasma concentration versus time curve(AUC) of ensartinib(reference product) after meal

    The AUC of ensartinib(reference product) in after meal blood samples of each subject over a 120 hour period post dose

    Time frame: pre-dose(60minute),30min,1,1.5,2,2.5,3,3.5,4,4.5,5,6,8,12,24,36,48,72,96,120hour

  8. Area under the plasma concentration versus time curve(AUC) of ensartinib(reference product) under fasted sate

    The AUC of ensartinib(reference product) in fasting blood samples of each subject over a 120 hour period post dose

    Time frame: pre-dose(60minute),30min,1,1.5,2,2.5,3,3.5,4,4.5,5,6,8,12,24,36,48,72,96,120hour

Secondary outcomes

  1. Percentage of participants with adverse events as assessed by CTCAE v4.03

    Time frame: from screening to post-study visit, assessed up to 28 days

07

Study locations

1 site
  • Shanghai Public Health Clinical Center
    Shanghai, Shanghai 201508, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Jan 2019, 6 months.

Of 129 industry-sponsored phase 1 interventional studies under Lung Neoplasms, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 57. This study's 6 months is below that.

Counting every sponsor, half of 292 studies reached it within 52 months; a quarter within 28 and three quarters within 74.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2018
First posted
May 24, 2018
StartActual
Jun 11, 2018
Primary completionActual
Jan 9, 2019
CompletionActual
Jan 9, 2019
Last update
Jul 24, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03536481
Responsible party
Sponsor
First posted
May 24, 2018
Start date
Jun 11, 2018
Primary completion
Jan 9, 2019
Completion
Jan 9, 2019
Last update
Jul 24, 2019

Study contacts

Tongyu Zhu
principal investigator · Shanghai Public Health Clinical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ensartinib

Start the discussion